相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Reid W. Merryman et al.
BLOOD ADVANCES (2021)
Hodgkin Lymphoma, Version 2.2020
Richard T. Hoppe et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis
Steven M. Bair et al.
ONCOLOGIST (2019)
PDL1 Fusion Protein Protects Against Experimental Cerebral Malaria via Repressing Over-Reactive CD8+ T Cell Responses
Jun Wang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study
Li Gao et al.
HEMATOLOGY (2019)
How I manage patients with relapsed/refractory diffuse large B cell lymphoma
Christian Gisselbrecht et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Hodgkin Lymphoma: A Review and Update on Recent Progress
Satish Shanbhag et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Diagnostic, prognostic and therapeutic role of CD30 in lymphoma
John Matthew R. Pierce et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Addition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review
Takahiro Aoki et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine et al.
LANCET (2016)
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Knut B. Smeland et al.
HAEMATOLOGICA (2015)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Alison J. Moskowitz et al.
LANCET ONCOLOGY (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Knut B. Smeland et al.
HAEMATOLOGICA (2015)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Oxaliplatin-Based Chemotherapy (Dexamethasone, High-Dose Cytarabine, and Oxaliplatin) ± Rituximab Is an Effective Salvage Regimen in Patients With Relapsed or Refractory Lymphoma
Luigi Rigacci et al.
CANCER (2010)
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
Mars B. van 't Veer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
分享论文
